The Wall Street Journal
Novo Inks Weight-Loss Licensing Deal With Hengrui Pharma — The Danish drugmaker signed a licensing deal for a weight-loss treatment being developed by China-based Hengrui Pharma that could be worth up to $2.6 billion.
Shein’s Earnings Disappoint, Sending Stock Lower — The China-founded company expects the external environment to remain uncertain in the second half of 2026.
The Nike Lifer Driving a High-Stakes Turnaround in China — Once one of its best ma
Subscribe or login to read the rest.
Subscribers get full access to:
- Exclusive longform investigative journalism, Q&As, news and analysis, and data on Chinese business elites and corporations. We publish China scoops you won't find anywhere else.
- A weekly curated reading list on China from Andrew Peaple.
- A daily roundup of China finance, business and economics headlines.
We offer discounts for groups, institutions and students. Go to our
Subscriptions page for details.
Includes images from Depositphotos.com
